AR and prostate carcinoma: A proportion of these patients are primarily resistant to the treatment, which may be caused by AR heterogeneity in prostate cancer [63, 64] and other alterations in enzymes crucial for the conversion of extragonadal precursors to potent androgens, such as the 3βHSD1 germline variant [4].